Get Your: Magazine | eNews | Free Info Packet

Fighting PKD Together

Since 1982, passionate patients have inspired and supported the PKD Foundation’s efforts to fight PKD. Together, we’ve advanced basic PKD research into PKD drug development. Treatments for PKD are finally within reach! Now, more than ever, we need to unite as a community - join us in this unfinished fight.

Learn

Connect

Tolvaptan Not Yet Approved to Treat PKD
May 19, 2009 | Research & Medicine

The FDA approved Tolvaptan (Samsca®) for use as a treatment for hyponatremia (low level of salt in the blood) on May 19, 2009. Tolvaptan works by blocking the receptor for vasopressin (anti-diuretic hormone) which results in the production of very dilute urine leading to correction of low levels of salt in the blood.

More News

RSS News Feed


Cure of ADPKD by selection for spontaneous genetic repair events in Pkd1-mutated iPS cells - PhysOrg Fri, 10 Feb 2012 07:17:47 -0500 Here we demonstrate restoration of a genomic mutation heterozygous for Pkd1 (polycystic kidney disease 1) deletion (Pkd1(+/-) to Pkd1(+/R+)) by spontaneous mitotic recombination. Notably, recombination between homologous chromosomes occurred at ...